THE TAPE
TEVA · Pharmaceutical Preparations · $49.6B

Teva Pharmaceutical Industries Limited

$42.57▼ −4.34%
Last close
Relative strength
89RS
of 99, against every stock▼ -5 on the month
Cooling off
Unconfirmed
+12.6%
six months against Pharmaceutical Preparations
52-week range
−4.5%
from the high
$24.01$44.57
Setup
vcpclimbing
+1.3%
against the pivot at $42.02
72 days
Jan 27 · not confirmed
Growth FLATProof SHOWN
Quarter to Sep 30, revenue −2% on a year ago
11/16 O 44.30 H 44.57 L 42.52 Vol 7.5M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS89
vs pivot+1.31%
Tightening1.14×
Dry-up1.66×
Up/down vol0.14
From high4%
failed pokeclimbing9 of 9checks
Cooling off
Support and resistance
Support below
$41.92
-1.5% · tested 3× · last 20 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.0 weeks and fell 7% from its ceiling at its deepest. The pivot is $42.02, and the stock closed 1.3% above that pivot. Its relative strength rating is 89.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-1.8%
Three months against its industry
+34.5%
Six months against its industry
+12.6%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap
72
days
Earnings in 72 days (not yet confirmed)
Jan 27, 2027
  1. Earningstentativein 72d
    Quarterly earnings
    Jan 27, 2027
How it moves on earnings

On average 10.3% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$17.2B
-1.9% year on year
Operating margin
8.3%
gross 53.5%
Net margin
2.9%
Free cash flow
$1.2B
2.5% of market cap
Price to sales
2.88×
Price to earnings
98.0×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$4.4B
+6.1% QoQ · -1.9% YoY
Gross margin
55.5%
+3.5 pts QoQ
Net income
$233.0M
Positive
Free cash flow
$121.0M
Cash generating

What the numbers say

  • Revenue -1.9% year over year, +6.1% on the quarter
  • Good: Gross margin 55.5%, +3.5 points on the quarter
  • Good: Profitable: net income $233M, operating margin 16.2%
  • Good: Cash generating: operating cash flow $241M, free cash flow $121M
  • Good: Net cash $47M · cash $4.08B
Revenue by quarter
Free cash flow
Net income
shares +1.6% in a year · net cash $47.0M
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-03
above 20d & 50d on 1.8x volume at 40.70
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
A director or officer changedFiling · 2026-10-30
5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
New 52-week highTape · 2026-10-12
2.9x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Unusual volumeTape · 2026-10-12
7.2 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Entered a material agreementFiling · 2026-09-17
1.01
No measurable effect: stocks behave like random ones over the next three sessions (866 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
25
$39,961,612 total

Sold: Sabag Mark, Daniell Richard, Francis Richard D, Weiss Amir, Bergwerk Dov, Savage Brian, MIGNONE ROBERTO, Satchi-Fainaro Ronit, Lippman Evan, Zaks Tal Zvi, Jover Placid, Hughes Eric A, Shields Matthew, Kalif Eliyahu Sharon.

Not counted above: 22 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-12 Sabag Mark · See "Remarks"option exercise44,710$1,560,379
2026-11-12 Sabag Mark · See "Remarks"sell44,710$1,973,544
2026-11-11 Daniell Richard · EVP, Europe Commercialoption exercise20,003$694,104
2026-11-11 Daniell Richard · EVP, Europe Commercialsell20,003$856,154
2026-11-10 Francis Richard D · President and CEOsell250,000$10,559,175
2026-11-09 Daniell Richard · EVP, Europe Commercialoption exercise25,000$867,500
2026-11-09 Daniell Richard · EVP, Europe Commercialsell25,000$1,072,790
2026-11-09 Weiss Amir · Chief Accounting Officeroption exercise7,755$269,099

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

9 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy4
Buy9
Hold2
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
3w · 7%

The most recent of 2 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Teva Pharmaceutical Industries Limited (TEVA) — The Tape